Darius Okonkwo

Operators at every site must own revenue-protecting decisions before claims enter the system.

Look for vendors that own the handoff between software automation and operator judgment.

Facility fees widen the reimbursement gap between hospitals and freestanding infusion centers.

Covered entities must embed 340B rules into infusion workflows to stay compliant.

Infusion programs face predictable audit failures in administrative compliance and documentation.

Infusion centers must meet entity, patient, and drug-level tests to access 340B pricing.

Biosimilar competition is collapsing reimbursement faster than practices can adjust.

Prior authorization denials in buy-and-bill infusion create unrecoverable financial losses.

Denial and underpayment require different strategies to protect biologic revenue.

Infusion practices vastly underestimate denial costs by tracking only lost reimbursement.